Patents by Inventor Haim Yellin
Haim Yellin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20070100001Abstract: The subject invention provides methods of treating a subject afflicted with Parkinson's disease, memory disorder, depression, hyperactive syndrome, Attention Deficit Disorder, dementia, brain ischemia, stroke, head trauma injury, spinal trauma injury, neurotrauma, neurodegenerative disease, neurotoxic injury, multiple sclerosis, nerve damage, affective illness, schizophrenia or symptoms of withdrawal from an addictive substance, using the mesylate salt of R(+)-N-propargyl-1-aminoindan.Type: ApplicationFiled: November 10, 2006Publication date: May 3, 2007Inventors: Moussa Youdim, John Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Tirtsah Berger-Paskin, Haim Yellin, Izila Yeilin, Alexander Veinberg
-
Publication number: 20060094783Abstract: The subject invention provides methods of treating a subject afflicted with Parkinson's disease, memory disorder, depression, hyperactive syndrome, Attention Deficit Disorder, dementia, brain ischemia, stroke, head trauma injury, spinal trauma injury, neurotrauma, neurodegenerative disease, neurotoxic injury, multiple sclerosis, nerve damage, affective illness, schizophrenia or symptoms of withdrawal from an addictive substance, using the mesylate salt of R(+)-N-propargyl-1-aminoindan.Type: ApplicationFiled: June 17, 2005Publication date: May 4, 2006Inventors: Moussa Youdim, John Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Tirtsah Berger-Paskin, Haim Yellin, Tzila Yellin, Alex Veinberg, Veinberg Alexander
-
Patent number: 6956060Abstract: The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an effective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.Type: GrantFiled: November 27, 2002Date of Patent: October 18, 2005Assignees: Teva Pharmaceutical Industries, Ltd., Technion Research and Development Foundation Ltd.Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Haim Yellin, Alex Veinberg
-
Publication number: 20030212145Abstract: The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an effective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.Type: ApplicationFiled: November 27, 2002Publication date: November 13, 2003Applicants: Teva Pharmaceutical Industries, Ltd., Technion Research Development Foundation, Ltd.Inventors: Moussa B.H. Youdim, John P.M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Haim Yellin, Alex Veinberg
-
Patent number: 6316504Abstract: The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing the same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject.Type: GrantFiled: November 16, 1998Date of Patent: November 13, 2001Assignees: Technion Research and Development Foundation, Ltd., Teva Pharmaceuticals Industries, Ltd.Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Haim Yellin, Alex Veinberg
-
Patent number: 5891923Abstract: This invention relates to the use of R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof for the treatment of dementia.Type: GrantFiled: June 6, 1995Date of Patent: April 6, 1999Assignees: Teva Pharmaceutical Industries Ltd., Technion Research and Development Foundation, Ltd.Inventors: Moussa B.H. Youdim, John P.M. Finberg, Ruth Levy, Haim Yellin
-
Patent number: 5786390Abstract: The subject invention relates to pharmaceutical composition of R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof.Type: GrantFiled: June 6, 1995Date of Patent: July 28, 1998Assignees: Teva Pharmaceutical Industries Ltd., Technion Research and Development Foundation Ltd.Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Tirtsah Berger-Paskin, Haim Yellin, Alex Veinberg
-
Patent number: 5744500Abstract: The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.Type: GrantFiled: May 22, 1995Date of Patent: April 28, 1998Assignees: Teva Pharmaceutical Industries, Ltd., Technion Research and Development Foundation Ltd.Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Haim Yellin, Alex Veinberg
-
Patent number: 5668181Abstract: This invention relates to the use of R(+)-N-propargyl-1-aminoindan.Type: GrantFiled: June 2, 1995Date of Patent: September 16, 1997Assignees: Teva Pharmaceutical Industries Ltd., Techion Research and Development Foundation Ltd.Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Tirtsah Berger-Paskin, Haim Yellin
-
Patent number: 5599991Abstract: The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, brain ischemia, a head trauma injury, a spinal trauma injury, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.Type: GrantFiled: June 6, 1995Date of Patent: February 4, 1997Assignees: Teva Pharmaceutical Industries Ltd., Technion Research and Development Foundation, Ltd.Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Haim Yellin, Alex Veinberg
-
Patent number: 5576353Abstract: R(+)-N-propargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.Type: GrantFiled: June 2, 1995Date of Patent: November 19, 1996Assignees: Teva Pharmaceutical Industries Ltd., Technion Research and Development Foundation, Ltd.Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Haim Yellin
-
Patent number: 5532415Abstract: The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, brain ischemia, a head trauma injury, a spinal trauma injury, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.Type: GrantFiled: March 28, 1995Date of Patent: July 2, 1996Assignees: Teva Pharmaceutical Industries Ltd., Technion Research and Development Foundation Ltd.Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Tirtsah Berger-Paskin, Haim Yellin, Alex Veinberg
-
Patent number: 5519061Abstract: The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, brain ischemia, a head trauma injury, a spinal trauma injury, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.Type: GrantFiled: June 6, 1995Date of Patent: May 21, 1996Assignees: Teva Pharmaceutical Industries Ltd., Technion Research and Development Foundation Ltd.Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Haim Yellin
-
Patent number: 5457133Abstract: R(+)-N-propargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.Type: GrantFiled: February 17, 1994Date of Patent: October 10, 1995Assignees: Teva Pharmaceutical Industries Ltd., Technion Research and Development Foundation Ltd.Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Tirtsah Berger-Paskin, Haim Yellin
-
Patent number: 5453446Abstract: R(+)-N-p-opargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.Type: GrantFiled: June 7, 1994Date of Patent: September 26, 1995Assignees: Teva Pharmaceutical Industries, Ltd., Technion Research and Development Foundation Ltd.Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Tirtsah Berger-Paskin, Haim Yellin
-
Patent number: 5387612Abstract: R(+)-N-propargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.Type: GrantFiled: May 18, 1993Date of Patent: February 7, 1995Assignees: Teva Pharmaceutical Industries Ltd., Technion Research and Development Foundation Ltd.Inventors: Mussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Tirtsah Berger-Paskin, Haim Yellin
-
Patent number: 4889724Abstract: Stable aqueous injectable Cisplatin solutions. The solutions comprise 0.1-1.0 mg/ml of Cisplatin, 9-15 mg/ml of NaCl and 0.025-0.075 mg/ml of citric acid. These solutions have the advantage of combining a mild pH range of 3.0-6.0 with a long shelf life.Type: GrantFiled: August 4, 1988Date of Patent: December 26, 1989Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Rodney Kasan, Michael Seiffe, Haim Yellin
-
Patent number: 4889929Abstract: Process for the preparation of 1'-ethoxy carbonyloxy ethyl esters of penicillins, wherein a compound of the formula ##STR1## in which A is phenyl, phenoxy or 4-hydroxyphenyl, B is hydrogen, an amino group or a protected amino group and Z is hydrogen or a cation selected from the group of alkali metal, tri (lower alkyl ) ammonium and tetra (lower alkyl) ammonium, is reacted with 1-bromoethyl ethyl carbonate in an organic solvent and when B is a protected amino group the protecting group is split off to yield a primary amino group.There are also provided novel compounds of the formula ##STR2## in which Ph is phenyl and R is CH.sub.3 -- or C.sub.2 H.sub.5 --.Type: GrantFiled: March 26, 1987Date of Patent: December 26, 1989Assignee: Astra Lakemedel AktiebolagInventors: Jacob Vaya, David Ladkani, Clara Schoenberger, Joseph Kaspi, Gad Salemnick, Haim Yellin, Stephan Cherkez
-
Patent number: 4883805Abstract: A stable, injectable pharmaceutical composition of vinca dimer salts. The compositions are in the form of an aqueous solution comprising per 1 ml of solution:from about 0.2 to about 2 mg of one or more pharmaceutically acceptable vinca dimer salts;from about 0.1 to about 1.0 mg of a pharmaceutically acceptable ethylenediamine-tetraacetic acid (EDTA) salt;acetate buffer in an amount necessary to maintain said aqueous solution at a pH of from about 3.0 to about 5.5; andfrom about 1.5 to about 2.5 mg of a preservative selected from methyl paraben, propyl paraben and mixtures thereof.Type: GrantFiled: July 28, 1987Date of Patent: November 28, 1989Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Rodney Kasan, Haim Yellin, Michael Seiffe
-
Patent number: 4851426Abstract: Novel esters of the general formula ##STR1## in which ##STR2## is the acyl residue of a non-steroidal anti-inflammatory compound containing a carboxylic acid function. The novel esters are prepared by reacting an acide R--COOH when R is as above, with 1-haloethyl ethyl carbonate. There are also provided pharmaceutical compositions containing any of the said novel esters.Type: GrantFiled: February 12, 1986Date of Patent: July 25, 1989Assignee: Teva Pharmaceutical Industries, Ltd.Inventors: David Ladkani, Haim Yellin, Ben Z. Weiner, David Avnir